Pyxis Oncology

PYXS · Nasdaq · United States

Share price · PYXS

$1.41-1.58 (-52.84%) 3M

close as of 2026-11-18 · 24h delayed · vol 765K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PYXS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Sep 2026-19.7%
  2. 11 Aug 2026-26.1%
  3. 6 Aug 2026+19.8%

    Nothing announced by PYXS that day or the session before.

  4. 7 Jul 2026+24.8%

    Nothing announced by PYXS that day or the session before.

  5. 26 Jun 2026+24.2%

    Nothing announced by PYXS that day or the session before.

  6. 26 May 2026-16.8%

    Nothing announced by PYXS that day or the session before.

  7. 14 May 2026-15.6%
  8. 8 May 2026+21.2%
  9. 6 May 2026+25.7%

    Nothing announced by PYXS that day or the session before.

  10. 24 Apr 2026+11.1%

    Nothing announced by PYXS that day or the session before.

Share of unusual movement by asset

For each asset, the share of PYXS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
MW02No recent activity
Phase 2/3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Phase 1/2
ED-B domain of fibronectinAntibody–drug conjugate
Solid Tumors

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Micvotabart pelidotinPhase 1/2Advanced Solid Tumors
Est. primary completion 2027-12-06 · NCT06795412 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2026Topline resultMicvotabart pelidotinPhase 1 monotherapy in 2L+ R/M HNSCC: 36% confirmed ORR (n=33)
US · Pyxis Oncology · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$17M$3.9M+ $52M short-term inv.$20M-$16M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$16M$19M+ $14M short-term inv.$25M-$18M operating cash flowreport ↗
2026-Q1—$20M$5.8M+ $35M short-term inv.$23M-$26M operating cash flowreport ↗
2025-Q3—$18M$8.9M+ $67M short-term inv.$22M-$13M operating cash flowreport ↗
2025-Q2$2.8M$17M$11M+ $78M short-term inv.$18M-$17M operating cash flowreport ↗
2025-Q1—$17M$13M+ $93M short-term inv.$21M-$23M operating cash flowreport ↗
2024-Q3—$18M$12M+ $133M short-term inv.$21M-$15M operating cash flowreport ↗
2024-Q2—$14M$25M+ $131M short-term inv.$17M-$3.0M operating cash flowreport ↗
2024-Q1$16M$13M$28M+ $129M short-term inv.$3.3M-$21M operating cash flowreport ↗
2023-Q3—$15M$15M+ $118M short-term inv.$23M-$18M operating cash flowreport ↗
2023-Q2—$11M$26M+ $117M short-term inv.$16M-$11M operating cash flowreport ↗
2023-Q1—$12M$53M+ $96M short-term inv.$19M-$27M operating cash flowreport ↗
2022-Q3—$19M$199M$28M-$21M operating cash flowreport ↗
2022-Q2—$17M$223M$26M-$24M operating cash flowreport ↗
2022-Q1—$20M$247M$31M-$28M operating cash flowreport ↗
2021-Q3—$7.8M$133M$14Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$14M$74M$15M+ $51M short-term inv.$20M-$64M operating cash flowreport ↗

Pyxis Oncology reported FY2025 revenue of $13.86M, down 14.2% YoY from $16.15M, with R&D spend of $73.7M, up 25.4% YoY from $58.75M. Cash and equivalents stood at $15.42M, and the company reported a net loss of $79.6M for the year.

The company guided that current cash, cash equivalents, and short-term investments should fund operations into Q4 2026. Clinically, target enrollment was completed in the Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ recurrent/metastatic head and neck squamous cell carcinoma in Q1 2026, with updated monotherapy data expected mid-2026 and updated combination data with KEYTRUDA expected in 2H26. Preliminary data showed a 46% confirmed objective response rate and 92% disease control rate for MICVO monotherapy, and a 71% confirmed ORR and 100% DCR in combination. The company also obtained FDA alignment on a planned pivotal monotherapy study and announced Thomas Civik as Interim CEO.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$16M$59M$19M+ $107M short-term inv.$19M-$58M operating cash flowreport ↗
2023-FY—$50M$9.7M+ $110M short-term inv.$18M-$71M operating cash flowreport ↗
2022-FY—$86M$179M$30M-$89M operating cash flowreport ↗
2021-FY—$51M$275M$19M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($0), 1 sale ($107K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06HUMPHREY RACHEL · directorAward / grant (derivative)34,500——Form 4
2026-10-01GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase (derivative)7,172,000——Form 4
2026-10-01GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase5,517,000——Form 4
2026-10-01GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase (derivative)7,546,766——Form 4
2026-09-04Civik Thomas · director, CEO & Chairman of the BoardAward / grant (derivative)2,503,050——Form 4
2026-08-20Dupont Jakob · directorAward / grant (derivative)46,000——Form 4
2026-08-12Civik Thomas · director, Interim CEOAward / grant (derivative)250,956——Form 4
2026-06-30Dupont Jakob · directorOption exercise35,000$1.60$56KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 27.6M shares ($40.3M, 23.1% of shares outstanding).

#InstitutionSharesValue
1Pfizer Inc7,032,770$9.2M
2Laurion Capital Management LP4,997,333$7.3M
3GordonMD Global Investments LP4,121,870$6.0M
4VANGUARD CAPITAL MANAGEMENT LLC2,033,510$3.0M
5Atle Fund Management AB197,036$1.6M
6Palo Alto Investors LP1,010,510$1.5M
7683 Capital Management, LLC896,263$1.3M
8RENAISSANCE TECHNOLOGIES LLC888,680$1.3M
9BlackRock, Inc.788,839$1.2M
10GEODE CAPITAL MANAGEMENT, LLC598,121$874K
11Longaeva Partners L.P.503,214$735K
12JACOBS LEVY EQUITY MANAGEMENT, INC460,997$673K
13MILLENNIUM MANAGEMENT LLC397,625$581K
14MARSHALL WACE, LLP354,417$517K
15Decheng Capital LLC326,810$477K